# Wearable Continuous Drug Monitoring Device for Personal Medications in Opioid Use Disorders (CDM-MOUD)

> **NIH NIH R43** · LABSYS, LLC · 2024 · $294,474

## Abstract

ABSTRACT
LabSys’s objective is to create a transformative wearable patch, designed as a low-cost
Continuous Drug Monitoring Device for Opioid Use Disorders (CDM-MOUD). Our state-of-the-art
patch utilizes a microneedle—so fine that it is painless—to monitor medication levels directly
within the interstitial fluid, a technique that has been shown to reliably mirror blood concentrations.
Our proprietary detection method can secure both sensitivity and specificity of the opioids at
concerned concentration range. This approach promises a leap forward in managing OUD by
providing uninterrupted insights into the effectiveness of treatment protocols. In our upcoming
Phase I research, our specific aims focus on engineering an alpha prototype with fentanyl sensing
capability. This initial model will integrate our patented electrochemical sensor technology with
low-power electrochemical impedance spectroscopy, coupled with seamless wireless
communication for real-time data transmission. This endeavor is not just about technology; it's
about people. As we refine our prototype, evaluating critical factors such as accuracy, response
time, and device longevity, we will engage with the potential customers. We will tailor the patch to
the nuanced needs of customers to ensure our product aligns with the real-world demands. Our
vision extends into Phase II, where we will further adapt our prototype for broader clinical use,
pursuing the FDA's “Breakthrough Devices Program” participation to meet rigorous regulatory
standards, and clinical trials to ensure the highest standards of patient safety and product efficacy.
LabSys's mission through this project is to empower individuals battling OUD with discreet,
continuous health monitoring, as essential as a glucose monitor. Our products will empower
patient-centered care, fostering better outcomes and facilitating a more personalized approach to
treatment. We believe that our CDM-MOUD has the potential to revolutionize opioid treatment
and offer a new beacon of hope for millions affected by the opioid crisis, particularly,
disadvantaged populations in low-resource settings.

## Key facts

- **NIH application ID:** 10984292
- **Project number:** 1R43DA061397-01
- **Recipient organization:** LABSYS, LLC
- **Principal Investigator:** Yue Huang
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $294,474
- **Award type:** 1
- **Project period:** 2024-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10984292

## Citation

> US National Institutes of Health, RePORTER application 10984292, Wearable Continuous Drug Monitoring Device for Personal Medications in Opioid Use Disorders (CDM-MOUD) (1R43DA061397-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10984292. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*